These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20155999)

  • 21. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
    Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z;
    Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
    Muresanu DF; Heiss WD; Hoemberg V; Bajenaru O; Popescu CD; Vester JC; Rahlfs VW; Doppler E; Meier D; Moessler H; Guekht A
    Stroke; 2016 Jan; 47(1):151-9. PubMed ID: 26564102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with Cerebrolysin.
    Molloy DW; Standish TI
    J Neural Transm Suppl; 2000; 59():293-300. PubMed ID: 10961441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
    Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
    J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrolysin Asian Pacific trial in acute brain injury and neurorecovery: design and methods.
    Poon W; Vos P; Muresanu D; Vester J; von Wild K; Hömberg V; Wang E; Lee TM; Matula C
    J Neurotrauma; 2015 Apr; 32(8):571-80. PubMed ID: 25222349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial.
    Gharagozli K; Harandi AA; Houshmand S; Akbari N; Muresanu DF; Vester J; Winter S; Moessler H
    J Med Life; 2017; 10(3):153-160. PubMed ID: 29075343
    [No Abstract]   [Full Text] [Related]  

  • 29. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.
    Muresanu DF; Alvarez XA; Moessler H; Novak PH; Stan A; Buzoianu A; Bajenaru O; Popescu BO
    J Neurol Sci; 2010 Dec; 299(1-2):179-83. PubMed ID: 20923712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study.
    Wong GK; Zhu XL; Poon WS
    Acta Neurochir Suppl; 2005; 95():59-60. PubMed ID: 16463821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior neuroprotective effects of cerebrolysin in heat stroke following chronic intoxication of Cu or Ag engineered nanoparticles. A comparative study with other neuroprotective agents using biochemical and morphological approaches in the rat.
    Sharma HS; Muresanu DF; Patnaik R; Stan AD; Vacaras V; Perju-Dumbrav L; Alexandru B; Buzoianu A; Opincariu I; Menon PK; Sharma A
    J Nanosci Nanotechnol; 2011 Sep; 11(9):7549-69. PubMed ID: 22097459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.
    Muresanu DF; Florian S; Hömberg V; Matula C; von Steinbüchel N; Vos PE; von Wild K; Birle C; Muresanu I; Slavoaca D; Rosu OV; Strilciuc S; Vester J
    Neurol Sci; 2020 May; 41(5):1171-1181. PubMed ID: 31897941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donepezil for dementia due to Alzheimer's disease.
    Birks J; Harvey RJ
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].
    Vereshchagin NV; Suslina ZA; Timerbaeva SL; Kashina EM; Gnezditskiĭ VV; Maksimova MIu; Rebrova OIu; Smirnova IN
    Ter Arkh; 2001; 73(4):22-7. PubMed ID: 11494441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke.
    Zhang L; Chopp M; Wang C; Zhang Y; Lu M; Zhang T; Zhang ZG
    J Neurol Sci; 2019 Mar; 398():22-26. PubMed ID: 30665068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid with or without vitamin B12 for cognition and dementia.
    Malouf M; Grimley EJ; Areosa SA
    Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
    Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
    Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].
    Gavrilova SI; Fedorova IaB; Kolykhalov IV; Odinak MM; Emelin AIu; Kashin AV; Selezneva ND; Kalyn IaB; Roshchina IF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):24-8. PubMed ID: 18833104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey R
    Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease.
    Wei ZH; He QB; Wang H; Su BH; Chen HZ
    J Neural Transm (Vienna); 2007; 114(5):629-34. PubMed ID: 17318304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.